Abstract:AIMS This double-blind, placebo-controlled trial was designed to evaluate the pharmacodynamics, pharmacokinetics, safety, and tolerability of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y(12) ADP receptor antagonist compared with clopidogrel, during multiple oral dosing in healthy subjects. METHODS Thirty subjects received placebo, prasugrel 5 mg, 10 mg, or 20 mg, or clopidogrel 75 mg orally, daily for 10 days. Platelet aggregation, bleeding time, and prasugrel metabolites were measured and adverse events were recorded. RESULTS Inhibition of ADP-induced platelet aggregation reached steady state by day 3 following prasugrel 10 and 20 mg compared with 5 days for clopidogrel 75 mg or prasugrel 5 mg. Compared with placebo, at 24 h after the last dose of study drug, inhibition of platelet aggregation using (20 microm) ADP was significantly higher in the prasugrel 10 mg group (58.2 +/- 4.9% vs. 9.2 +/- 4.0%, P < 0.001) with no difference in the clopidogrel group (15.7 +/- 6.8% vs. 9.2 +/- 4.0%, P = 0.78). With 5 microm ADP, inhibition of platelet aggregation with prasugrel 10 mg and clopidogrel 75 mg was significantly higher than with placebo (prasugrel 10 mg, 70.5 +/- 4.7%; clopidogrel 75 mg, 36.5 +/- 9.0%; vs. placebo, 11.3 +/- 5.1%; P < 0.0001 and P = 0.02). On day 10 at 4 h postdose, bleeding time was prolonged with prasugrel 10 mg (prasugrel 10 mg, 706 +/- 252 s vs. placebo, 221 +/- 38 s, P = 0.05) but not with clopidogrel (283 +/- 56 s, P = 0.98). There were no clinically significant bleeding events, serious adverse events, or discontinuations of the study drug. CONCLUSIONS Compared with clopidogrel 75 mg, prasugrel 10 mg and 20 mg daily for 10 days resulted in more rapid, more consistent, and higher levels of platelet inhibition.

Generation of Megawatt Peak-power Femtosecond Pulses from an Excessive-Normal-Dispersion Fiber Laser

Nonlinearity Optimization of Dissipative-Soliton Fiber Laser for Generation of Pulses with 350 Kw Peak Power

66 fs, 3 W all fiber Yb3+-doped mode-locked fiber laser

Vector-dispersion Compensation and Pulse Pedestal Cancellation in a Femtosecond Nonlinear Amplification Fiber Laser System.

Above 100 Nj All-Normal-dispersion Femtosecond Pulse Generation from a Large-Core Multi-Mode Fiber Laser

Femtosecond Mode-locked Fiber Laser at 1 Μm Via Optical Microfiber Dispersion Management

Textural interface opacity after Descemet‐stripping automated endothelial keratoplasty

High-Power GHz Burst-Mode All-Fiber Laser System with Sub 300 fs Pulse Duration

Generation Of Ultra-Stable 50-Fs Pulses Directly From An Er-Doped Fiber Oscillator

High Energy (100 Mj) and High Peak Power (8 MW) Nanosecond Pulses Delivered by Fiber Lasers and Self-Focusing Analysis Based on a Novel Mode Decomposition Method

Generation of a 59 Fs Pulse with a 550 Nm Spectral Range in a Mode-Locked Er-doped Single-Mode Fiber Laser System

Generation of high-energy self-mode-locked pulses in a Tm-doped fiber laser

Super-continuum generation using noise-like pulses from a large normal dispersion passively mode locking fiber laser

High Energy and High Peak Power Nanosecond Pulses Generated by Fiber Amplifier

Generation of 583 fs optical pulses at 10 GHz from a regeneratively mode-locked fiber laser combining nonlinear polarization evolution

900 MHz Fundamental Repetition Rate Femtosecond Er:fiber Laser Mode Locked by Nonlinear Polarization Evolution

A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans.

Generation of high-power 780 nm femtosecond pulses by an all-polarization-maintaining Er-doped fiber amplification system

Generation of sub-30 fs pulses from an erbium-doped fiber amplifier at 203 MHz repetition rate

Generation of ultrafast laser with 11 MW peak power from a gain-managed nonlinear tapered fiber amplifier

Higher-order Mode Fiber Enables High Energy Chirped-Pulse Amplification.